Acknowledgment We would like to thank Ms. Catherine Gillespie for the professional editing and proofreading of the chapter. Introduction Central nervous system (CNS) tumors are a diverse group of neoplasms that have been classified by the World Health Organization (WHO)…
Introduction The success of chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma has led to interest in developing CAR T-cell treatments for other malignancies. The modular nature of the CAR brought hope that simply…
Disclaimer The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. Introduction Treatment…
Background CD19 chimeric antigen receptor-T (CAR T) cell therapy has dramatically improved the outcomes for pediatric and adult patients with short-term complete remission (CR) rates of approximately 90% in relapsed/refractory B-lineage acute lymphoblastic leukemia (ALL) and objective response rates (ORRs)…
Introduction Chimeric antigen receptor (CAR)–modified T-cell immunotherapy is highly effective for patients with relapsed and/or refractory B-cell malignancies, but significant adverse effects remain a concern. Systemic cytokine release syndrome (CRS) can occur in association with the inflammatory cytokine surge during…
Introduction Chimeric antigen receptor (CAR)–modified T-cell immunotherapy can be a highly effective treatment for patients with relapsed and/or refractory hematologic malignancies, but significant adverse effects remain a concern. Systemic cytokine release syndrome (CRS) can occur in association with the inflammatory…
Cancer is among the leading causes of death worldwide. The number of new cancer cases per year is expected to rise to 23.6 million by 2030. Advancements in oncology therapeutics and associated improvements in survival mean that more patients may…
Acknowledgments COI disclosures: Dr. Lee serves on the external advisory board for Juno Therapeutics/Celgene, has provided ad hoc consulting to Harpoon Therapeutics, and has received clinical trial research support from Kite Introduction Chimeric antigen receptor (CAR) T-cell therapy has been…
Acknowledgments We thank ML Silverberg for assistance with development of nursing and postinfusion protocols. Screening Once identified as a candidate for chimeric antigen receptor (CAR) T-cell therapy, patients must undergo screening for eligibility. Prediagnostic evaluations are required to assess patient…
Introduction Chimeric antigen receptor (CAR) T-cells are one of the most rapidly growing cancer immunotherapies, particularly for B-cell malignancies. While the manufacturing of CAR T-cells is relatively straightforward, there are many barriers associated with the manufacturing process. Additionally, most CAR…